Literature DB >> 16225628

Topical pimecrolimus: a novel therapeutic option for Netherton syndrome.

V Oji, G Beljan, K Beier, H Traupe, T A Luger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16225628     DOI： 10.1111/j.1365-2133.2005.06884.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

Review 1.  Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues.

Authors:  Seth J Orlow
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 2.  The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.

Authors:  Johannes Ring; Matthias Möhrenschlager; Verena Henkel
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Netherton syndrome caused by compound heterozygous mutation, c.80A>G mutation in SPINK5 and large-sized genomic deletion mutation, and successful treatment of intravenous immunoglobulin.

Authors:  Zhen Zhang; Chaolan Pan; Ruoqu Wei; Huaguo Li; Yijun Yang; Jiawen Chen; Ming Li; Zhirong Yao
Journal:  Mol Genet Genomic Med       Date:  2021-01-16       Impact factor: 2.183

Review 4.  Netherton Syndrome in Children: Management and Future Perspectives.

Authors:  Federica Barbati; Mattia Giovannini; Teresa Oranges; Lorenzo Lodi; Simona Barni; Elio Novembre; Ermanno Baldo; Mario Cristofolini; Stefano Stagi; Silvia Ricci; Francesca Mori; Cesare Filippeschi; Chiara Azzari; Giuseppe Indolfi
Journal:  Front Pediatr       Date:  2021-05-10       Impact factor: 3.418

5.  Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.

Authors:  Laetitia Furio; Simon de Veer; Madeleine Jaillet; Anais Briot; Aurelie Robin; Celine Deraison; Alain Hovnanian
Journal:  J Exp Med       Date:  2014-02-17       Impact factor: 14.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.